TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Optimizing Function and Independence Through STRIDE

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Inclusion/Exclusion listed here apply to subset of patients providing consent for telephone interviews:~* Able and willing to provide informed consent (does not lack decision-making capacity)~* Discharged from a participating hospital within the preceding 30 days~* Age \>= 60~* Index admission for medical illness~* Community-dwelling (i.e. not in a nursing home or institutional care) prior to hospital visit~* Ability to ambulate safely and independently (does not need help walking across a small room)~* Valid telephone number in the medical record~* Admitted to a STRIDE ward and discharged from a STRIDE ward~* Index hospital stay was in a ward identified to participate in the STRIDE program~Exclusion Criteria:~* Patient deceased~* Index hospital stay was \< 2 business days~* Currently hospitalized~* Current high-risk suicide flag in medical record~* Diagnosis of cognitive impairment or dementia~* Difficulty with or unable to communicate on the telephone, or no telephone access~* Discharged to another hospital or acute care setting~* Transferred into index hospital from another hospital~* Bedrest order not lifted for at least 2 days on STRIDE ward

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): Implementation of STRIDE program
- Usual Care (Type: NO_INTERVENTION): Pre-implementation before STRIDE program

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Diclofenac Sodium Gel in Knee Osteoarthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Key Inclusion criteria~* OA of the knee Key Exclusion criteria~* Other rheumatic disease, such as rheumatoid arthritis~* Active gastrointestinal ulcer during the last year~* Known allergy to analgesic drugs

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open Label, 4 Week Study of ITCA 650 in Adults With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* type 2 diabetes \>6 months~* stable diet \& exercise, metformin, TZD or met + TZD HbA1c \>6.5% \<10.0%~Exclusion Criteria:~* prior treatment with exenatide~* history of pancreatitis~* history of medullary thyroid cancer or multiple endocrine neoplasia 2

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 10 mcg./day (Type: EXPERIMENTAL): ITCA 650 (exenatide in DUROS)
- 20 mcg/day (Type: EXPERIMENTAL): ITCA 650 (exenatide in DUROS)
- 40 mcg/day (Type: EXPERIMENTAL): ITCA 650 (exenatide in DUROS)
- 80 mcg/day (Type: EXPERIMENTAL): ITCA 650 (exenatide in DUROS)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically-confirmed advanced solid tumor, chronic lymphocytic leukemia, small lymphocytic lymphoma, T-cell prolymphocytic leukemia, Non-Hodgkin Lymphoma or multiple myeloma~* Progressed or not tolerated standard therapy, and no further standard therapy is available~* Archival and screening tumor biopsy~* Eastern Cooperative Oncology Group Performance Status: 0 or 1~* Adequate organ function~Exclusion Criteria:~* Prior cancer-directed modalities or investigational drugs within 4 wks or 5 half lives, whichever is shorter~* Symptomatic brain metastases (prior treatment and stable metastases are allowed)~* Acute or chronic renal disease or pancreatitis~* Diarrhea ≥ Grade 2, impaired gastrointestinal absorption~* Impaired cardiac function~* History of diabetes requiring treatment, glucose \>126 mg/dL, Glycated hemoglobin (HbA1c) ≥6.5%~* Peripheral neuropathy ≥ Grade 2~* Known Human Immunodeficiency Virus (HIV) infection, chronic hepatitis B or C (unless associated with hepatocellular cancer)~* Pregnant, inadequate contraception, breast feeding~* Most concurrent second malignancies~* Part B only: Prior treatment with agents targeting both mammalian target of rapamycin (mTOR) complexes (dual mammalian target of rapamycin complex 1/2 inhibitors) and/or PI3K/AKT pathways. However, prior treatment with isolated target of rapamycin complex 1 (TORC1) inhibitors (eg., rapalogs) is allowed in both parts of this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CC-115 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Acarbose Versus Glibenclamide on MAGE and Oxidative Stress in Patients With Type 2 DM

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients may be included in the clinical trial only if they meet all of the following criteria:~  1. Male or female outpatients;~ 2. Age 30 - 70 years;~ 3. Patients have failed to achieve glycemic control with diet, exercise and max. 2 OHA; Hemoglobin A1c level between 7.0 to 11.0 % at V1 and 7-11.5 % at V4.~ 4. Diagnosis of diabetes mellitus is over a minimum 3-month period;~ 5. All patients give written informed consent;~ 6. For female patients of childbearing potential, the following criteria will be applied:~* Using adequate contraception since last menses and will continue to use adequate contraception during the clinical trial.~* Not lactating.~* Negative pregnancy test (urine) within 7 days prior to the first dose of study medication. (Note: the inclusion criterion 6 does not apply to menopausal female).~Exclusion Criteria:~* Patients will be excluded from the clinical trial for any of the following reasons:~  1. Patients with a serum creatinine concentration greater than 132.6 mmol/L (1.5 mg/dL) or liver function impairment (AST and ALT 2.5 times upper limit of normal range);~ 2. Patients have laboratory test abnormality (biochemistry, hematology, or urinalysis), which in the investigator's opinion might confound the clinical trial. However, patients with hyperlipemia, elevated cholesterol or triglyceride levels, or lipid metabolism disorders are eligible;~ 3. Use of chronic insulin therapy;~ 4. Patients with medical conditions that could promote lactic acidosis, such as renal or hepatic disease, unstable angina, congestive heart failure (New York Heart Association Functional Classification III and IV), or chronic obstructive pulmonary disease, e.g. respiratory insufficiency, hypoxemic condition;~ 5. Patients with a history of hypersensitivity to metformin hydrochloride, glibenclamide or acarbose;~ 6. Patients receive an investigational drug within 30 days prior to admission to the clinical trial;~ 7. Patients with significant alcohol, drug or medication abuse as judged by the investigator.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- acarbose, glibenclamide (Type: ACTIVE_COMPARATOR): acarbose vs. glibenclamide (background metformin therapy)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Analysis of Adherence and Effectiveness Outcomes Between Rheumatoid Arthritis (RA) Patients Treated With Tofacitinib Modified Release (MR)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* At least one claim for tofacitinib between 01 January 2014 and 31 January 2017 (the identification period).~* Presence of The International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9 CM) code for RA (in any position) during the one-year pre-index period or on the index date. ICD-9 = 714.0x-714.4x \& 714.81 or ICD10 = M05.\* \& M06.0\*-M06.3\* or M06.8\*-M06.9\*.~* At least 18 years old as of the index date.~Exclusion Criteria:~* Patients with claims for other conditions for which biologics are used during the one-year pre-index period or on the index date: ankylosing spondylitis, Crohn's disease, psoriasis, psoriatic arthritis, or ulcerative colitis will be excluded from the study.~* Patients with evidence of the index medication during the one-year pre-index period will be removed from the analysis. Patients will be allowed to have been treated with other biologics approved for RA (Tumor-Necrosis Factor-alpha inhibitors (TNFi) \[adalimumab (Humira), etanercept (Enbrel), certolizumab pegol (Cimzia), golimumab (Simponi), infliximab (Remicade)\] and non-TNFi's with alternative mechanisms of action \[abatacept (Orencia), and rituximab (Rituxan), anakinra (Kineret), tocilizumab (Actemra)\]) during the one-year pre-index period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Truven Health MarketScan Research Database (Type: None): individuals who are privately insured and with Medicare Supplemental insurance

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Friedreich's ataxia patients completing core study SNT-III-002 (NCT00537680) and presenting at Week 24 (Visit 5) of that study~* Body weight ≥ 25kg/55 lbs~* Negative urine pregnancy test~* Patients who in the opinion of the investigator are able to comply with the requirements of this study~Exclusion criteria:~* Adverse events during the course of SNT-III-002(NCT00537680)which in the opinion of the investigator are attributable to idebenone and preclude further treatment with idebenone~* Clinically significant abnormalities of clinical hematology or biochemistry including, but not limited to, elevations greater than 2 times the upper limit of normal of AST, ALT or creatinine~* Treatment with coenzyme Q10, vitamin E (if taken at a dose 5 times above the daily requirement) or other sources of idebenone within the past month~* Parallel participation in another clinical drug trial~* Past or present history of abuse of drugs or alcohol~* Pregnancy or breast-feeding

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): high dose Idebenone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating the Safety and Efficacy of CLONICEL® to Treat Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female between 6 and 17 years of age, inclusive~* Diagnosis of ADHD of the hyperactive or combined inattentive/hyperactive subtypes according to DSM-IV criteria~* Minimum score of 26 on the ADHDRS-IV questionnaire at Baseline~* General good health as judged by the Principal Investigator~* Body mass index ≥ 5th percentile of the subject's age group according to the CDC growth chart.~* Ability to swallow tablets~* General IQ ≥80 as judged by the Principal Investigator~* Subject as well as parent/guardian able to sign informed assent or consent form.~Exclusion Criteria:~* If female of child-bearing potential, pregnant or lactating or does not agree to use a medically acceptable form of birth control, such as hormonal medication, double-barrier method, or IUD~* Presence of a clinically significant illness or abnormality on physical examination or clinical laboratory evaluations that, in the opinion of the investigator, would increase the safety risks from clonidine administration or interfere with the ability of the patient to take part in the study.~* Presence of clinically significant abnormality on centrally interpreted Electrocardiogram (ECG) readings~* History or presence of a concomitant psychiatric disorder requiring psychotropic medication or a severe concomitant Axis I or Axis II disorder that could interfere with study assessments in the judgment of the Principal Investigator~* History of concomitant conduct disorder (CD)~* History of seizures, except for a single episode of febrile seizure prior to age 2~* History of syncopal episodes~* Presence of a disorder that would interfere with the absorption, metabolism, or excretion of clonidine~* History of intolerance to clonidine, including any dermatologic reaction to transdermal clonidine~* Presence or history of alcohol or drug abuse~* Positive drug screen, with the exception of ADHD drugs~* Use of any investigational drug within 30 days of study start.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): CLONICEL High Dose
- 2 (Type: EXPERIMENTAL): CLONICEL Low Dose
- 3 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Participant who gave written informed consent to participate in the study in accordance with local regulations.~* Adult participants 18 years and older with a diagnosis of T1D made at least 1 year prior to informed consent.~* Participants treated with insulin or insulin analog delivered via continuous subcutaneous insulin infusion (CSII) or multiple daily injections (MDI).~* Willing and were able to perform Self-monitoring of blood glucose (SMBG) and completed the study diary as required per protocol.~* At the Screening Visit, A1C was between 7.0% to 11.0%.~* Females of childbearing potential must use an adequate method of contraception and have a negative pregnancy test.~Exclusion Criteria:~* Use of antidiabetic agent other than insulin or insulin analog at the time of screening.~* Use of sodium-glucose cotransporter (SGLT) inhibitors within 8 weeks prior to screening.~* Chronic systemic corticosteroid use.~* Type 2 diabetes mellitus (T2DM), or severely uncontrolled T1D as determined by the Investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Two placebo-matching sotagliflozin tablets, once daily, orally, before the first meal of the day for 24 weeks followed by a 28-week extension period.
- Sotagliflozin 200 mg (Type: EXPERIMENTAL): Sotagliflozin 200 milligram (mg) (one 200 mg tablet and one placebo tablet), once daily, orally, before the first meal of the day for 24 weeks followed by a 28-week extension period.
- Sotagliflozin 400 mg (Type: EXPERIMENTAL): Sotagliflozin 400 mg (two 200 mg tablets), once daily, orally, before the first meal of the day for 24 weeks followed by a 28-week extension period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Compare the Efficacy and Safety of Different Dosings of Olodaterol Administered With the Respimat® Inhaler in Patients With Moderate to Severe Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Patients of either sex.~2. Aged 18 to 70 years.~3. A current diagnosis and a documented minimum 3 month history of asthma Global Initiative for Asthma (GINA) treatment steps 3 and 4.~4. Prebronchodilator Forced Expiratory Volume in one second (FEV1) \>= 60% predicted and \< 90% predicted according to European Coal and Steel Community (ECSC).~5. Increase in FEV1 \>=12% and \>=200 mL 15 min. after 400 µg salbutamol (albuterol);~6. Stable on medium to high dose inhaled corticosteroids (ICS) or low to high dose ICS in combination with a long acting beta-adrenergics (LABA) for at least 6 weeks prior to screening. Stable on ICS mono component of the former fixed LABA/ICS treatment for at least 48 hours prior to Visit 1b.~Exclusion criteria:~1. Patients with a significant disease other than asthma.~2. History of frequent seasonal exacerbations of asthma (defined as one or more seasonal exacerbations every year for the past three years).~3. Upper respiratory tract infection in the past 3 weeks prior to screening visit 1b.~4. Oral or other systemic corticosteroids in the past 6 weeks.~5. Patients with allergen desensitization therapy if started within two years, if they are not on an established maintenance regimen characterized by dose adjustments but no further increase to the tolerable maximum in the same course of immunotherapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Olodaterol medium daily dose (Type: EXPERIMENTAL): Olodaterol medium daily dose given either as once daily or split into two low doses daily or placebo only in randomised sequence of three cross-over treatment phases
- Olodaterol high daily dose (Type: EXPERIMENTAL): Olodaterol high daily dose given either as once daily or split into two medium doses daily or placebo only in randomised sequence of three cross-over treatment phases

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Injection Versus Splinting in Carpal Tunnel Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female aged ≥ 18 years~* A clinical diagnosis of unilateral or bilateral CTS as made by a GP or trained clinician according to the diagnostic criteria~* Mild (e.g. intermittent paraesthesia) or moderate (e.g. constant paraesthesia, reversible numbness and / or pain) severity CTS of idiopathic nature~* Symptom duration of episode of at least 6 weeks~* Written informed consent provided by the patient, prior to any trial specific procedures~Exclusion Criteria:~* Steroid injection or night splints for CTS in the affected wrist within preceding 6 months~* Any previous surgery on the affected wrist~* Severe CTS exhibiting constant numbness or pain, constant sensory loss, severe thenar muscle atrophy or symptom severity which requires the patient to be referred for a surgical opinion~* Clinical suspicion of local or systemic sepsis or infection~* Current or previous infection of the affected wrist~* Trauma to the affected hand requiring surgery or immobilisation in the previous 12 months~* Unable to tolerate the study interventions~* Unable to understand and complete self-report questionnaires written in English~* Inter-current illness including, but not limited to:~  * poorly controlled thyroid disease~ * poorly controlled diabetes mellitus~ * vibration-induced neuropathy~ * inflammatory joint disease~ * suspected complex neurological conditions~ * any other severe medical illness which in the opinion of the local Principal Investigator (or other authorised clinical delegate) precludes trial participation~* Pregnant or lactating females~* Receiving anticoagulants~* Any history of hypersensitivity to Depo-Medrone or any of its excipients~* Allergy to any of the splint materials~* Known abuse of drugs or alcohol~* Involved in on-going litigation cases for their condition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Steroid Injection (Type: ACTIVE_COMPARATOR): Single steroid injection into Carpal Tunnel (as Depo-medrone 20mg)
- Wrist Splint (Type: ACTIVE_COMPARATOR): Wrist splint to be worn at night

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete